Noxopharm Limited (NOX:ASX)

53.0¢

right-arrow Created with Sketch. -0.035 (-6.19%)
MCAP $165.1M
Last trade 15.59pm 19/10/2021 20mins delayed

Latest Announcements

15/10/2021NOXNoxopharm Limited
15/10/2021NOXNoxopharm Limited
14/10/2021 Price SensitivePSNOXNoxopharm Limited
29/09/2021NOXNoxopharm Limited
202
MCap
29/09/2021NOXNoxopharm Limited
27/09/2021 Price SensitivePSNOXNoxopharm Limited
10/09/2021NOXNoxopharm Limited
09/09/2021NOXNoxopharm Limited

Company Overview

Noxopharm Limited is an Australia-based clinical-stage drug development company. The Company is focused on the treatment of cancer and cytokine release syndrome or septic shock. The Company is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The Company's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The Company's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).

NOX in the news

Noxopharm (NOX) is planning to extend the trials of its COVID-19 treatment…
Noxopharm (NOX) teams up with the US National Cancer Institute (NCI) to…
Noxopharm (NOX) confirms that combining its Veyonda drug with LuPSMA in prostate…
Noxopharm (NOX) receives the green light from the US Food and Drug…

Search Previous Announcements